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The aim was to examine the risk profiles and prognosis
of treated and untreated hypertensive subjects and
examine to what degree confounding by indication
was present in a population-based cohort study with
up to 30-year follow-up. The study population consisted
of 9328 men and 10 062 women, aged 33–87 years at the
time of attendance from 1967 to 1996. The main outcome
measures were myocardial infarction (MI), cardiovascu-
lar disease (CVD) mortality and all-cause mortality.
Comparing the risk profiles between treated and un-
treated subjects entering the study showed significantly
higher values for some risk factors for treated subjects.
During the first 10 years, hypertensive men without
treatment, compared with those treated, had a signifi-
cantly lower risk of suffering MI, CVD and all-cause
mortality, hazard ratio (HR) 0.72 (95% CI; 0.57, 0.90), 0.75
(95% CI; 0.59, 0.95) and 0.81 (95% CI; 0.61, 0.98),
respectively. No significant differences in outcome were
seen during the following 20 years. In identically defined
groups of women, no significant differences in mortality
were seen between groups. Subgroup analysis, at two
stages of the study 5 years apart, revealed that some
cardiovascular risk factors had a higher prevalence in
hypertensive men who were treated at the later stage,
compared with those who remained untreated
(P¼ 0.004). In conclusion, hypertensive treated men
had a worse prognosis during the first 10 years of
follow-up than untreated ones, which is most likely due
to worse baseline risk profile. Hypertensive men that
were treated at a later stage had a worse risk profile than
those not treated at a later stage.
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Introduction
Hypertension is a serious risk factor for many
common causes of morbidity and mortality, includ-
ing stroke, myocardial infarction (MI), congestive
heart failure and end-stage renal disease.1–3 This
disorder affects about a quarter of the adult popula-
tion in industrialized societies.4,5 Several clinical
trials have confirmed the benefit of treatment in
preventing cardiovascular morbidity and mortality,
particularly stroke and coronary artery disease.6,7
Other trials have not shown benefit from treatment
of coronary artery disease and all-cause mortality.8,9
Most clinical trials have been carried out on selected
groups of patients and individuals, where the
highest-risk individuals are usually excluded.10–12
Thus, the documented effects of treatment in a trial
may have less general validity than is often
assumed.12 Therefore, epidemiological studies are
important in considering the effect of treatment in
the community. Only a few epidemiological studies
have been carried out, where the aim was to assess
the possible benefits of long-term treatment (45
years) of hypertension.12–14
An inherent problem in comparing the outcome of
nonrandomized treatment groups, such as treated
and untreated hypertensives, in an epidemiological
setting is the complexity of the treatment indication
that may be affected by associated risk factors. The
prognosis of the treated patients may be different
from that in the untreated subjects. The indication
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for drug use may confound comparison so that it
looks as if the treatment induces the disease rather
than curing it. One term suggested for this biased
observation is confounding by indication.15–17 The
objectives of the present study were to examine
thoroughly the risk profiles and prognosis of treated
and untreated hypertensive men and women and to
examine the effects of antihypertensive treatment in
the community. The aims were also to compare the
risk score of hypertensive subjects before they were
treated, in those who were treated later vs those who
remained untreated, in order to examine to what
degree confounding by indication was present.
Methods
The Reykjavik Study, initiated in 1967, is a
prospective, population-based study that includes
participants from Iceland’s capital city, Reykjavik,
and adjacent communities. In 1968, the population
of the area was around 104 000, close to half the total
population of Iceland at that time. The study cohort
(30 795 participants, 14 923 men and 15 872 women)
was selected from the National Roster, a computer-
ized, continuously updated population register
established in 1953, based on a compulsory, lifetime
personal identification number. The cohort was
divided into six comparable groups and examined
in six successive stages between 1967 and 1996. The
design of the study and invitation to participate has
previously been described in detail.18,19 Some of the
groups were invited to attend more than once. The
men attended 18 495 times and women 18 281 times,
a response rate of 70.9% for men and 70.1% for
women.18,19 Loss to follow-up during the whole
study was o0.5%.19 Every participant received an
invitation letter that included standardized ques-
tions about health and social factors, including the
Rose chest pain questionnaire.20 The participants in
the present study are the men (2792) and women
(2642) that fulfilled the set criteria from all stages of
the Reykjavik Study.
Examinations
Participants came in a fasting state to the clinic.
After 5 min rest, the supine blood pressure was
measured, on two occasions, between 0830 and 1030
hours, by a nurse, and 10–14 days later between
1100 and 1330 hours, by a physician. The subjects
were not instructed to be fasting at the second blood
pressure measurement. The instruments used were
mercury sphygmomanometers of the type ‘Erka-
meter’ wall-model (Erka, Germany). The cuffs had
a rubber bladder 15 cm 32 cm, and the total length
of the cuff was 66 cm. The same types of cuffs and
instruments were used throughout the study. The
procedure followed in measuring blood pressure
was according to WHO recommendations.21 The
diagnosis of hypertension was based on the mean of
two measurements: systolic blood pressure
X160 mmHg and/or diastolic blood pressure
X95 mmHg. Subjects on antihypertensive medica-
tion were considered to be hypertensive.
A standardized 12-lead resting electrocardiogram
was recorded and read according to the Minnesota
code.22 Subjects were classified as having suffered a
definite symptomatic MI if hospital records fulfilled
the MONICA criteria for definite MI.23 If the
subject’s electrocardiograph (ECG) fulfilled the
criteria for definite MI (Minnesota codes 1:1:
1-1:3:6, 4:1-4:4, 5:1-5:4), but there was no history
or symptoms of heart attack, the participant was
classified as having had an unrecognized or silent
MI.18 From the outset of the study, the same
personnel have delivered the examining question-
naires, and the same physician (NS) has read and
coded the ECGs. Quality control of the ECG coding
has been through the World Health Organization
Reference Centre for ECG coding at the Hungarian
Institute of Cardiology in Budapest. Blood chemis-
try, fasting blood glucose from a capillary blood
sample and lipid profiles were measured using the
standard techniques of each time period since
1967.24,25
Follow-up procedures
After entering the study, subjects were followed for
up to 30 years (up to 1998) through the National
Roster, using the International Classification of
Diseases (ICD-9). The following endpoint categories
were used in this study: fatal and nonfatal MI ICD-9:
410–414; total cardiovascular disease (CVD) mortal-
ity ICD-9: 390–459; and all-cause mortality ICD-9:
001–999.
Statistics
First, a composite risk score based on results from
the first visit of all attendants (9328 men and 10 062
women) was computed for each gender and each of
the following endpoints: fatal and nonfatal MI, total
CVD and all-cause mortality. The composite risk
between treated and untreated hypertensive subjects
at first visit was compared. The composite risk
scores were calculated by forming the sum of
products of beta coefficients from Cox regression,
using all measurements at first visit and each
individual’s values of the risk factors
composite risk score ¼
X
ðbiVariÞ
for each person, where the beta coefficient (bi) is the
natural logarithm of relative risk for variable i and
Vari is the value of variable number i for each
person. The established risk factors used were
calendar year, age, total cholesterol, fasting glucose,
left ventricular hypertrophy, serum triglycerides,
protein- or glucosuria, smoking and manifestations
of previous coronary heart disease (known and
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unrecognized infarct, angina and ST-T changes).11,26
Blood pressure and its treatment were not included
in the composite risk score, being the main variables
under study. When the composite risk score for MI
was calculated, subjects with previous MI were
omitted. The survivor functions adjusted to mean
values of composite risk score of each of the groups
treated and not treated (for hypertension) were
computed. This was done in order to evaluate the
profile of risk from established risk factors for each
group without regard to blood pressure and anti-
hypertensive treatment.
Second, the hazard ratio (relative risk) was
analysed for three endpoints: MI (fatal and nonfatal),
total CVD mortality and all-cause mortality. Ordin-
ary Cox regression27 was applied except when the
risk period was bisected, and then time-dependent
Cox regression was used, adjusted for composite risk
score. Two hypertensive groups were compared:
hypertensive subjects who were not treated and
hypertensive subjects who were treated. The com-
posite risk score was included in the regression for
adjustment. The risk period of 30 years was divided
into two intervals, 0–10 years and 11–30 years, in
order to analyse changes in hazard ratio due to
regression dilution bias.28
Third, a subgroup analysis was performed for
hypertensive men and women who later were
treated vs those who remained untreated. This was
carried out to compare the risk profile between two
groups before they were treated with antihyperten-
sive medication.
Subjects used in the analysis attended the study
twice, were hypertensive on both visits, untreated
on the first visit, and either treated or not treated on
the second visit. In this analysis only stages II–III of
the Reykjavik Study were used, 1970–1975 for men
and 1971–1976 for women. The average time
between the stages was 5 years (range 3–6.4 years)
for men and 6 years (range 4–7.7 years) for women.
Subjects present at both stages II and III were
included. CVD risk factors of both subgroups were
compared at stage II when neither group was
receiving treatment. The CVD composite risk score
and a survivor function were calculated for the
subgroups. The software package used was SPIDA.29
Results
The analysis included 2792 hypertensive men, or
29.9% of male attendants, and 2642 hypertensive
women, or 26.3% of female attendants, all diag-
nosed on their first visit to the clinic. The number of
endpoints reached for men was about twice the
number for women during follow-up (Table 1).
Risk profiles of treated vs untreated hypertensives
When comparing characteristics at the first exam-
ination, distinct differences were found between
hypertensive subjects without treatment and those
who were treated. A similar pattern for men and
women was seen (Table 2). Subjects who were
hypertensive and treated at the first examination
entered the study later than those who were
hypertensive and untreated. The average age was
significantly higher for the treated men and women
than for hypertensive subjects without treatment.
After adjusting for age and the year of entry into
study, systolic/diastolic blood pressure was signifi-
cantly lower (Po0.0001) at the first visit for treated
men and women than for the group not treated. After
adjusting for age and the year of entry into study,
previous MI was more prevalent among the hyper-
tensive men (7.7%) and women (2.4%) who were
treated than for the groups not treated (5.1% for men
and 1.2% for women; P¼ 0.011 and 0.022, respec-
tively). The difference in composite risk between
treated and untreated subjects entering the study
was significantly in favour of those untreated
(Table 3), mostly due to a higher prevalence of
Table 1 Number of subjects and endpoints in the Reykjavik Study 1967–1998
Number of subjects (%) Number of endpoints
Fatal and nonfatal MI (%) CVD mortality (%) All-cause mortality (%)
Men 9328
Hypertensive 2792 (29.9)a
treated 692 (24.8)b 222 (32.1) 211 (30.5) 355 (51.3)
not treated 2100 (75.2) 630 (30.0) 635 (30.2) 1086 (51.7)
Women 10062
Hypertensive 2642 (26.3)a
treated 1196 (45.3)b 184 (15.4) 199 (16.6) 381 (31.9)
not treated 1446 (54.7) 227 (15.7) 250 (17.3) 544 (37.6)
MI¼myocardial infarction; CVD¼ cardiovascular disease.
a29.9% of the men were hypertensive vs 26.3% of the women; the difference was significant, Po0.001.
b24.8% of the hypertensive men were treated vs 45.3% of the women, the difference was significant, Po0.001.
Mean follow-up time for fatal and nonfatal MI was 18.7 years for men and 19.2 years for women.
Mean follow-up time for CVD and all-cause mortality was 19.7 years for men and 19.6 years for women.
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established coronary heart disease among the trea-
ted, compared with those not treated.
Hazard for treated vs untreated hypertensives
During the first 10 years, hypertensive men without
treatment, compared with those treated, had a
significantly lower risk of suffering an MI, a lower
risk of CVD mortality and a lower risk of all-cause
mortality (Table 4), even when a composite risk
score was taken into account. During the period of
11–30 years, the risk was between 0.89 and 1.09
(Table 4). The risk over the first 10 years of
cardiovascular mortality and all-cause mortality
was close to one for women, but the risk of suffering
MI was 0.81 for hypertensive women without
treatment, compared with those treated. The risk
Table 2 Characteristics at first examination of hypertensive men and women
Hypertensive men Hypertensive women
treated not treated treated not treated
Characteristics Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Number of subjects 692 2100 1196 1446
Year entering study 1980 (6.9) 1974 (5.7) 1982 (7.6) 1975 (7.3)
Age (years) 59.8 (9.5) 53.9 (9.0) 61.6 (10.1) 56.2 (9.5)
Total cholesterol (mmol/l) 6.3 (1.1) 6.5 (1.1) 6.9 (1.2) 7.0 (1.3)
Triglycerides (mmol/l) 1.6 (1.1) 1.4 (0.8) 1.4 (0.8) 1.1 (0.5)
Fasting glucose (mmol/l) 4.8 (1.1) 4.8 (1.0) 4.7 (1.2) 4.5 (0.8)
BMI (kg/m2) 27.6 (3.8) 26.9 (3.7) 28.6 (5.2) 26.4 (4.7)
Systolic blood pressure (mmHg) 157.1 (22.4) 161.6 (16.6) 155.3 (22.5) 166.3 (16.3)
Diastolic blood pressure (mmHg) 95.8 (11.7) 100.2 (8.6) 89.6 (11.3) 97.4 (8.9)
% Cases % Cases % Cases % Cases
Protein- or glucosuria 10.0 (69) 3.5 (73) 2.6 (31) 2.3 (33)
Left ventricle hypertrophy 6.5 (45) 5.4 (114) 1.4 (17) 1.4 (20)
Previous MI 7.4 (51) 2.6 (55) 2.5 (30) 0.6 (9)
Previous unrecognized infarction 1.3 (9) 0.6 (12) 1.3 (15) 0.7 (10)
Angina 5.2 (36) 2.3 (49) 5.3 (63) 3.7 (54)
ST-T changes 16.0 (111) 9.4 (197) 12.8 (153) 12.2 (176)
Current smokers 35.8 (248) 48.7 (1022) 25.9 (309) 31.6 (457)
Former smokers 40.2 (278) 27.6 (580) 19.9 (238) 15.8 (228)
Table 3 Risk profile and predicted 10-year survival of treated and untreated hypertensive men and women without regard to blood
pressure and antihypertensive treatment
Men Women
MI CVD All-cause MI CVD All-cause
Composite risk scorea for
hypertensiveb treated 5.49 5.49 5.09 7.74 7.48 5.29
hypertensive not treated 5.06 4.91 4.55 7.21 6.85 4.80
Difference 0.44 0.58 0.53 0.53 0.62 0.49
P-valuec o0.0001 o0.0001 o0.0001 o0.0001 o0.0001 o0.0001
Predicted 10-year survivald for
hypertensive treated (%) 84.2 88.1 82.1 93.7 94.6 89.6
hypertensive not treated (%) 88.9 92.3 88.4 95.8 96.7 93.0
Difference (%) 4.7 4.2 6.3 2.1 2.1 3.4
aComposite risk score at baseline was comprised of risk factors significantly predictive in the Cox model for all-cause mortality, CVD mortality
and MI. The risk factors used were year of entry into study, age, total cholesterol, fasting glucose, left ventricular hypertrophy, serum triglycerides,
protein- or glucosuria, smoking, known infarct, silent infarct, angina and ST-T changes. Known and silent infarct were not included in composite
risk score for MI.
bHypertension was defined at first visit as systolic blood pressure (BP)X160 mmHg and/or diastolic BPX95 mmHg.
cP-values are from the t-test.
dPredicted 10-year survival is taken from a calculated survivor function (which is adjusted for the mean values of the baseline composite risk
scores). This was done in order to evaluate the profile of risk from established risk factors for each group without regard to blood pressure and
antihypertensive treatment.
MI¼myocardial infarction, fatal and nonfatal; CVD¼ cardiovascular disease mortality; All-cause¼ all-cause mortality.
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over the 11- to 30-year period for hypertensive
women without treatment, compared with those
treated, of MI, CVD mortality and all-cause mortality
was not significantly different from 1.
Risk profiles of hypertensive men and women who
were later treated vs those who were not later treated
The risk profile for the two groups was examined at
first attendance for men and women (Table 5). The
average age for hypertensive men who were treated
later was 50.5 years and 52.3 years for hypertensive
men who were not treated later (P¼ 0.005). The
average age for women in the two groups was
identical, 51.3 years. There was no difference in
examination year between the two groups for men
and women, respectively. As can be seen in Table 5,
hypertensive men and women who were treated
later had significantly higher systolic/diastolic
blood pressure, a difference of 15.3/6.5 mm Hg and
9.4/5.5 mmHg, respectively, compared with hyper-
tensive men and women who were not treated later.
Hypertensive women who were treated later had
significantly fewer cases of angina at first visit than
hypertensive men and women who were not treated
later. Hypertensive men who were treated later had a
higher prevalence of ST-T changes and protein and/
or glucosuria than hypertensive men who were not
treated later. The difference in frequency of ST-T
changes and protein- or glucosuria was not signifi-
cant between hypertensive women who were treated
later and hypertensive women who were not treated
later. The composite risk score for CVD mortality
was significantly higher for the hypertensive men
who were treated later than for those who were not
treated later, a difference of 0.33 (P¼ 0.004). For
women the difference was 0.059 and not signifi-
cant (P¼ 0.73).
Discussion
In this longitudinal study we found that during the
first years of follow-up, hypertensive men who were
not treated were at significantly lower risk of
coronary heart disease than hypertensive, treated
men. This was not seen for women. When entering
the study, the risk profiles for hypertensive men and
women on treatment were significantly worse than
for hypertensive men and women who were not
treated. Subgroup analysis showed higher blood
pressure and a higher level of some cardiovascular
risk factors in hypertensive men who were treated
later, compared with hypertensive men who were
not treated later. The decision to treat seems to have
been affected by the baseline risk profile, that is
there was confounding by indication.
The results from the whole follow-up might
suggest that antihypertensive treatment was not
beneficial, or that there was confounding by indica-
tion in the study. During the first years of follow-up,
hypertensive men who were not treated were
significantly less likely than treated men to suffer
fatal or nonfatal MI, and had lower CVD mortality
and all-cause mortality. When looking at the risk
within 2-year periods during the first 10 years for
men (data not shown), the risk of MI, CVD mortality
Table 4 Hazard ratio (HR) for hypertensivea men, not treated (2100) vs treated (692), and hypertensive women, not treated (1446) vs
treated (1196), using Cox regression, adjusting for composite risk scoreb, the Reykjavik Study, 1967–1998
Men Women
Endpoints Follow-up years HRc (RR) 95% CId HRc (RR) 95% CId
All-cause mortality 0–10 0.81 (0.66, 0.98) 0.92 (0.72, 1.17)
11–30 0.89 (0.74, 1.07) 0.95 (0.78, 1.15)
0–30 0.85 (0.74, 0.97) 0.93 (0.80, 1.09)
CVD mortality 0–10 0.75 (0.59, 0.95) 0.96 (0.70, 1.32)
11–30 0.96 (0.76, 1.22) 0.81 (0.62, 1.06)
0–30 0.85 (0.72, 1.01) 0.87 (0.71, 1.07)
MI (fatal and nonfatal) 0–10 0.72 (0.57, 0.90) 0.81 (0.58, 1.12)
11–30 1.09 (0.82, 1.43) 0.91 (0.68, 1.21)
0–30 0.86 (0.72, 1.02) 0.86 (0.69, 1.07)
aHypertension was defined at first visit as systolic blood pressure (BP)X160 mmHg and/or diastolic BPX95 mmHg.
bComposite risk score was comprised of risk factors significantly predictive in the Cox model for all-cause mortality, CVD mortality and MI. The
risk factors used were year of entry into study, age, total cholesterol, fasting glucose, left ventricular hypertrophy, serum triglycerides, protein- or
glucosuria, smoking, known infarct, silent infarct, angina and ST-T changes. Subjects with a history of known or silent MI were not included in
composite risk score for MI.
cHR, which is equivalent to relative risk (RR), was calculated using Cox regression, with the hypertensive treated controlled group as a reference
category. The time periods used were 0–10, 11–30 and 0–30 years of follow-up.
dCI denotes confidence interval.
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and all-cause mortality for the treated men started
off significantly higher and then gradually reached
that of the untreated ones. This was not seen for
women. A possible explanation is that there were
fewer endpoints among hypertensive women than
men. This gave wider confidence intervals for the
hazard ratios, especially for the first 10 years of
follow-up, and made interpretation of results for the
women less reliable. If we assume that worse
prognosis during the first 10 years for the treated
men were due to worse baseline risk profile
(confounding by indication), then the results
for 11–30 years, which show no significant differ-
ence in relative risk between treated and un-
treated men, may either indicate a late benefit of
treatment for the men or it could be a weakening of
the effect of difference in baseline risk profile over
time.
When subjects entered the study, various risk
factors for CVD mortality were more severe among
hypertensive treated men and women than among
hypertensive men and women that were not treated,
including previous MI, previously unrecognized
infarction and angina. Also, when entering the
study, the composite risk score for all three end-
points was significantly higher for treated subjects.
This consistent difference in composite risk score
strongly suggests confounding by indication. Pa-
tients with more ominous risk profiles were more
likely to be treated with antihypertensive drugs,
regardless of differences in blood pressure values.
This kind of prescription habit has been recom-
mended in both European and American guidelines
of antihypertensive treatment, since the objective of
antihypertensive treatment is to lower overall risk.30
Confounding by indication was further shown in
the subgroup analysis for men, but apart from higher
blood pressure, this was not found in women. For
example, we could not adjust for the pretreatment
blood pressure values, which were considerably
higher in hypertensive men and women who were
treated later than in hypertensive subjects who were
not treated later, as was shown in the subgroup
analysis.
Table 5 The subgroups ‘hypertensive later treated’ were hypertensive subjects without treatment at first attendance in the study and
treated for hypertension at a second attendance (about 5 years later). The subgroups ‘hypertensive later not treated’ were hypertensive
subjects without treatment at first and second attendance
Hypertensive men Hypertensive women
treated later not treated later treated later not treated later
Characteristics Mean (SEM) Mean (SEM) P-value Mean (SEM) Mean (SEM) P-value
Number of subjects 136 442 86 83
Year entering study 1971 (0.02) 1971 (0.04) 0.83 1973 (0.05) 1973 (0.05) 0.54
Age (years) 50.5 (0.31) 52.3 (0.54) 0.005 51.3 (0.72) 51.3 (0.62) 1.0
Total cholesterol (mmol/l) 6.42 (0.08) 6.57 (0.05) 0.13 6.86 (0.13) 6.86 (0.99) 0.99
Triglycerides (mmol/l) 1.33 (0.06) 1.43 (0.04) 0.05 1.08 (0.05) 1.11 (0.05) 0.98
Fasting glucose (mmol/l) 4.90 (0.11) 4.66 (0.04) 0.05 4.51 (0.10) 4.40 (0.06) 0.36
Systolic blood pressure (mmHg) 177.6 (1.66) 162.3 (0.71) 0.0001 176.7 (1.96) 167.3 (1.54) 0.0002
Diastolic blood pressure (mmHg) 107.8 (0.91) 101.3 (0.36) 0.0001 103.5 (0.93) 98.0 (0.88) 0.0001
% Cases % Cases P-value % Cases % Cases P-value
Protein and/or glucosuria 8.1 (11) 2.0 (9) 0.002 2.4 (2) 2.5 (2) 0.65
Left ventricle hypertrophy 6.6 (9) 5.0 (22) 0.60 1.2 (1) 1.2 (1) 0.76
Previous MI 2.2 (3) 0.7 (3) 0.29 0.0 (0) 0.0 (0)
Previous unrecognized infarction 0.0 (0) 0.2 (1) 1.0 1.2 (1) 0.0 (0) 1.0
Angina 0.7 (1) 2.3 (10) 0.43 0.0 (0) 9.6 (8) 0.01
ST-T changes 17.7 (24) 5.0 (22) 0.0007 11.6 (10) 10.8 (9) 0.93
Current smokers 41.1 (56) 46.6 (206) 22.1 (19) 25.3 (21)
Former smokers 36.0 (49) 27.4 (121) 0.15a 16.3 (14) 21.1 (17) 0.61a
(SEM) P-value (SEM) P-value
Difference in composite risk score for CVD mortalityb 0.33 (0.12) 0.004 0.06 (0.33) 0.73
Difference in predicted 10-year survivalc (%) 1.4 0.2
aP for trend.
bDifference in composite risk score: hypertensive later treated  hypertensive later not treated (same method used as in Table 3).
cDifference in predicted 10-year survival taken from a calculated survivor function: hypertensive later treated  hypertensive later not treated
(same method used as in Table 3).
P-values from t-test, w2 and Fisher’s exact test as appropriate.
Risk profiles of hypertensive men and women
LS Gudmundsson et al
620
Journal of Human Hypertension
The subgroup analysis also showed a higher level
of some cardiovascular risk factors (ST-T changes,
protein or glucose in urine) in hypertensive men
who were treated later than in those who were not
treated later, resulting in significantly higher cardi-
ovascular disease risk scores in those who were
treated later. On the other hand, angina was
significantly more prevalent among hypertensive
women who were not treated later. This was not the
case when comparing treated and untreated subjects
upon entry to the study, which showed a higher
prevalence of angina among treated subjects than
among untreated ones. There is no obvious explana-
tion for this finding, but the number of endpoints
was small.
This is an observational study where treatment is
not randomly assigned and confounding by indica-
tion is strongly suggested. In spite of attempts to
account for multiple confounders in the Cox model,
a complete correction cannot be accomplished,
resulting in residual confounding at baseline. This
could explain why the treated men have worse
prognosis during the first years after baseline
compared to the untreated men even after statisti-
cally adjusting for the differences in baseline risk
profiles. Even after adjusting for known risk factors,
a residual confounding may occur because of
measurement error or unmeasured or unknown risk
factors.31
The analysis of the whole cohort is limited to a
single examination when subjects entered the study.
It cannot control for changes in compliance or a shift
of subjects between categories during the study
period. Although we adjust for the year of entry into
the study, the possibility of crossover is clearly
present. During follow-up, hypertensive subjects
without treatment at entry into the study may have
been treated later, especially since treatment of
hypertension was getting more common.24 Addi-
tionally, in the present study there was systematic
referral of hypertensive individuals to physicians.32
This causes some misclassification that underesti-
mates the true effect of treatment and results in bias
toward the null.
In conclusion, hypertensive treated men had a
worse prognosis during the first 10 years of follow-
up than untreated ones, which is most likely due to
a worse baseline risk profile among the treated men.
Hypertensive men who were treated at a later stage
had a worse risk profile than those who were not
treated at a later stage.
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